Advances and challenges toward a vaccine against Chagas disease

Human Vaccines

Volumn 7, Issue 11, 2011, Pages 1184-1191

  Quijano Hernandez, Israel ^a,b   Dumonteil, Eric ^a,c  

^a UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MÉXICO   (Mexico)

^c TULANE UNIVERSITY   (United States)

Author keywords

American trypanosomiasis; Animal model; Pre clinical development; Trypanosoma cruzi; Vaccine

Indexed keywords

BENZNIDAZOLE; CPG OLIGODEOXYNUCLEOTIDE; CRUZIPAIN; DNA VACCINE; GAMMA INTERFERON; NIFURTIMOX; PROTOZOAL VACCINE; TOLL LIKE RECEPTOR;

CHAGAS DISEASE; COST EFFECTIVENESS ANALYSIS; CROSS REACTION; DRUG EFFICACY; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; MICROBIAL IMMUNITY; NONHUMAN; PARASITE TRANSMISSION; PARASITEMIA; REVIEW; TREATMENT DURATION; TRYPANOSOMA CRUZI; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINE PRODUCTION;

EID: 81855189522     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.11.17016     Document Type: Review

References (106)

1. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375:1388-402; PMID:20399979; DOI:10.1016/S0140-6736(10)60061-X.
2. Pérez-Molina JA, Perez-Ayala A, Moreno S, Fernandez-Gonzalez MC, Zamora J, Lopez-Velez R. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009; 64:1139-47; PMID:19819909; DOI:10.1093/jac/dkp357.
3. Lescure FX, Le Loup G, Freilij H, Develoux M, Paris L, Brutus L, et al. Chagas disease: changes in knowledge and management. Lancet Infect Dis 2010; 10:556-70; PMID:20670903; DOI:10.1016/S1473-3099(10)70098-0.
4. Castro JA, de Mecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol 2006; 25:471-9; PMID:16937919; DOI:10.1191/0960327106 het653oa.
5. Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis 2010; 51:69-75; PMID:20932171; DOI:10.1086/656917.
6. Muratore CA, Batista Sa LA, Chiale PA, Eloy R, Tentori MC, Escudero J, et al. Implantable cardioverter defibrillators and Chagas' disease: results of the ICD Registry Latin America. Europace 2009; 11:164-8; PMID:19056745; DOI:10.1093/europace/eun325.
7. Castillo-Riquelme M, Guhl F, Turriago B, Pinto N, Rosas F, Martinez MF, et al. The costs of preventing and treating chagas disease in Colombia. PLoS Negl Trop Dis 2008; 2:336; PMID:19015725; DOI:10.1371/journal.pntd.0000336.
8. Dias JC, Silveira AC, Schofield CJ. The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz 2002; 97:603-12; PMID:12219120; DOI:10.1590/S0074-02762002000500002.
9. Schofield CJ, Jannin J, Salvatella R. The future of Chagas disease control. Trends Parasitol 2006; 22:583-8; PMID:17049308; DOI:10.1016/j.pt.2006. 09.011.
10. Lee BY, Bacon KM, Connor DL, Willig AM, Bailey RR. The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. PLoS Negl Trop Dis 2010; 4:916; PMID:21179503; DOI:10.1371/journal.pntd.0000916
11. Montenegro VM, Jimenez M, Pinto Dias JC, Zeledon R. Chagas disease in dogs from endemic areas of Costa Rica. Mem Inst Oswaldo Cruz 2002; 97:491-4; PMID:12118277; DOI:10.1590/S0074-02762002000400006.
12. Crisante G, Rojas A, Teixeira MM, Anez N. Infected dogs as a risk factor in the transmission of human Trypanosoma cruzi infection in western Venezuela. Acta Trop 2006; 98:247-54; PMID:16797466; DOI:10.1016/j.actatropica.2006.05.006.
13. Estrada-Franco JG, Bhatia V, Diaz-Albiter H, Ochoa-Garcia L, Barbabosa A, Vazquez-Chagoyan JC, et al. Human Trypanosoma cruzi infection and seropositivity in dogs, Mexico. Emerg Infect Dis 2006; 12:624-30; PMID:16704811.
14. Gürtler RE, Cecere MC, Lauricella MA, Cardinal MV, Kitron U, Cohen JE. Domestic dogs and cats as sources of Trypanosoma cruzi infection in rural northwestern Argentina. Parasitology 2007; 134:69-82; PMID:17032467; DOI:10.1017/S0031182006001259.
15. Reithinger R, Ceballos L, Stariolo R, Davies CR, Gurtler RE. Extinction of experimental Triatoma infestans populations following continuous exposure to dogs wearing deltamethrin-treated collars. Am J Trop Med Hyg 2006; 74:766-71; PMID:16687678.
16. Kjos SA, Snowden KF, Craig TM, Lewis B, Ronald N, Olson JK. Distribution and characterization of canine Chagas disease in Texas. Vet Parasitol 2008; 152:249-56; PMID:18255233; DOI:10.1016/j.vet-par.2007.12.021.
17. ., Garg N, Bhatia V. Current status and future prospects for a vaccine against American trypanosomiasis. Expert Rev Vaccines 2005; 4:867-80; PMID:16372882; DOI:10.1586/14760584.4.6.867.
18. Cazorla SI, Frank FM, Malchiodi EL. Vaccination approaches against Trypanosoma cruzi infection. Expert Rev Vaccines 2009; 8:921-35; PMID:19538117; DOI:10.1586/erv.09.45.
19. Dumonteil E. Vaccine development against Trypanosoma cruzi and Leishmania species in the post-genomic era. Infect Genet Evol 2009; In press; PMID:19805015; DOI:10.1016/j.meegid.2009.02.009.
20. Kierszenbaum F. Chagas' disease and the autoimmunity hypothesis. Clin Microbiol Rev 1999; 12:210-23; PMID:10194457.
21. Tarleton RL, Zhang L. Chagas Disease Etiology: Autoimmunity or Parasite Persistence? Parasitol Today 1999; 15:94-9; PMID:10322321; DOI:10.1016/S0169- 4758(99)01398-8.
22. Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J Infect Dis 1999; 180:480-6; PMID:10395865; DOI:10.1086/314889.
23. DosReis GA. Evasion of immune responses by Trypanosoma cruzi, the etiological agent of Chagas disease. Braz J Med Biol Res 2011; 44:84-90; PMID:21243314; DOI:10.1590/S0100-879X2011007500005.
24. Ouaissi A, Da Silva AC, Guevara AG, Borges M, Guilvard E. Trypanosoma cruzi-Induced Host Immune System Dysfunction: A Rationale for Parasite Immunosuppressive Factor(s) Encoding Gene Targeting. J Biomed Biotechnol 2001; 1:11-7; PMID:12488621; DOI:10.1155/S1110724301000055.
25. Alba Soto CD, Solana ME, Poncini CV, Pino-Martinez AM, Tekiel V, Gonzalez-Cappa SM. Dendritic cells devoid of IL-10 induce protective immunity against the protozoan parasite Trypanosoma cruzi. Vaccine 2010; 28:7407-13; PMID:20850535; DOI:10.1016/j.vaccine.2010.08.105.
26. Ouaissi A, Guilvard E, Delneste Y, Caron G, Magistrelli G, Herbault N, et al. The Trypanosoma cruzi Tc52-released protein induces human dendritic cell maturation, signals via Toll-like receptor 2, and confers protection against lethal infection. J Immunol 2002; 168:6366-74; PMID:12055254.
27. Alvarez MN, Peluffo G, Piacenza L, Radi R. Intraphagosomal peroxynitrite as a macrophage-derived cytotoxin against internalized Trypanosoma cruzi: consequences for oxidative killing and role of microbial peroxiredoxins in infectivity. J Biol Chem 2011; 286:6627-40; PMID:21098483; DOI:10.1074/jbc.M110. 167247.
28. + T cells in Trypanosoma cruzi infection. Curr Opin Immunol 2009; 21:385-90; PMID:19646853; DOI:10.1016/j.coi.2009.07.006.
29. Parodi C, Padilla AM, Basombrio MA. Protective immunity against Trypanosoma cruzi. Mem Inst Oswaldo Cruz 2009; 104:288-94; PMID:19753487; DOI:10.1590/S0074-02762009000900038.
30. + T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infect Immun 2009; 77:4383-95; PMID:19651871; DOI:10.1128/IAI.01459-08.
31. Sardinha LR, Mosca T, Elias RM, do Nascimento RS, Goncalves LA, Bucci DZ, et al. The liver plays a major role in clearance and destruction of blood trypomastigotes in Trypanosoma cruzi chronically infected mice. PLoS Negl Trop Dis 2010; 4:578; PMID:20052269; DOI:10.1371/journal.pntd.0000578.
32. + T cell response and protection against heterotopic challenge. Infect Immun 2011; 79:3397-406; PMID:21628516; DOI:10.1128/IAI.01080-10.
33. Basombrio MA. Trypanosoma cruzi: partial prevention of the natural infection of guinea pigs with a killed parasite vaccine. Exp Parasitol 1990; 71:1-8; PMID:2113004; DOI:10.1016/0014-4894(90)90002-T.
34. Basombrío MA, Besuschio S. Trypanosoma cruzi culture used as vaccine to prevent chronic Chagas' disease in mice. Infect Immun 1982; 36:351-6; PMID:6804390.
35. Zuñiga C, Palau T, Penin P, Gamallo C, de Diego JA. Protective effect of Trypanosoma rangeli against infections with a highly virulent strain of Trypanosoma cruzi. Trop Med Int Health 1997; 2:482-7; PMID:9217704; DOI:10.1111/j.1365-3156.1997.tb00171.x.
36. Basso B, Cervetta L, Moretti E, Carlier Y, Truyens C. Acute Trypanosoma cruzi infection: IL-12, IL-18, TNF, sTNFR and NO in T. rangeli-vaccinated mice. Vaccine 2004; 22:1868-72; PMID:15121297; DOI:10.1016/j.vaccine.2003.11.013.
37. Basso B, Moretti E, Fretes R. Vaccination with epimastigotes of different strains of Trypanosoma rangeli protects mice against Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz 2008; 103:370-4; PMID:18660992; DOI:10.1590/S0074-02762008000400010.
38. Zuñiga E, Motran C, Montes CL, Diaz FL, Bocco JL, Gruppi A. Trypanosoma cruzi-induced immunosuppression: B cells undergo spontaneous apoptosis and lipopolysaccharide (LPS) arrests their proliferation during acute infection. Clin Exp Immunol 2000; 119:507-15; PMID:10691924; DOI:10.1046/j.1365-2249.2000.01150.x.
39. Taibi A, Plumas-Marty B, Guevara-Espinoza A, Schöneck R, Pessoa H, Loyens M, et al. Trypanosoma cruzi: immunity-induced in mice and rats by trypomastigote excretory-secretory antigens and identification of a peptide sequence containing a T cell epitope with protective activity. J Immunol 1993; 151:2676-89; PMID:7689612.
40. Wrightsman RA, Miller MJ, Saborio JL, Manning JE. Pure paraflagellar rod protein protects mice against Trypanosoma cruzi infection. Infect Immun 1995; :122-5; PMID:7806347.
41. Miller MJ, Wrightsman RA, Manning JE. Trypanosoma cruzi: protective immunity in mice immunized with paraflagellar rod proteins is associated with a T-helper type 1 response. Exp Parasitol 1996; 84:156-67; PMID:8932765; DOI:10.1006/expr.1996.0101.
42. Frank FM, Petray PB, Cazorla SI, Munoz MC, Corral RS, Malchiodi EL. Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. Vaccine 2003; 22:77-86; PMID:14604574; DOI:10.1016/S0264-410X(03)00541-3.
43. Crampton A, Vanniasinkam T. Parasite vaccines: the new generation. Infect Genet Evol 2007; 7:664-73; PMID:17702669; DOI:10.1016/j.meegid.2007.06.004.
44. Dumonteil E. DNA vaccines against protozoan parasites: opportunities and challenges. J Biomed Biotechnol 2007; 2007:90520; PMID:17710244; DOI:10.1155/2007/90520.
45. + T cell epitope at two distinct regions of the genome. Virol J 2011; 8:127; PMID:21418577; DOI:10.1186/1743-422X-8-127.
46. + T cells against Trypanosoma cruzi infection. Int J Parasitol 2010; 40:1549-61; PMID:20620143; DOI:10.1016/j.ijpara.2010.05. 011.
47. +-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun 2005; 73:7356-65; PMID:16239534; DOI:10.1128/IAI.73.11.7356-65.2005.
48. + T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2006; 2:77; PMID:16879036; DOI:10.1371/journal.ppat.0020077.
49. + T cells leading to immunodominance. J Immunol 2008; 180:1737-48; PMID:18209071.
50. Haolla FA, Claser C, de Alencar BC, Tzelepis F, de Vasconcelos JR, de Oliveira G, et al. Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection. Vaccine 2009; 27:5644-53; PMID:19635607; DOI:10.1016/j.vaccine.2009.07.013.
51. + T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance. J Immunol 2010; 185:560-8; PMID:20530265; DOI:10.4049/jimmunol.1000432.
52. Bhatia V, Garg NJ. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice. Clin Vaccine Immunol 2008; 15:1158-64; PMID:18550728; DOI:10.1128/CVI.00144-08.
53. Gupta S, Garg NJ. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice. PLoS Negl Trop Dis 2010; 4:797; PMID:20706586; DOI:10.1371/journal.pntd.0000797.
54. Tekiel V, Alba-Soto CD, Gonzalez Cappa SM, Postan M, Sanchez DO. Identification of novel vaccine candidates for Chagas' disease by immunization with sequential fractions of a trypomastigote cDNA expression library. Vaccine 2009; 27:1323-32; PMID:19162108; DOI:10.1016/j.vaccine.2008.12.056.
55. García EA, Ziliani M, Aguero F, Bernabo G, Sanchez DO, Tekiel V. TcTASV: a novel protein family in Trypanosoma cruzi identified from a subtractive trypomastigote cDNA library. PLoS Negl Trop Dis 2010; 4:841; PMID:20957201; DOI:10.1371/journal.pntd.0000841.
56. Ouaissi A, Aguirre T, Plumas Marty B, Piras M, Schoneck R, Gras Masse H, et al. Cloning and sequencing of a 24-kDa Trypanosoma cruzi specific antigen released in association with membrane vesicles and defined by a monoclonal antibody. Biol Cell 1992; 75:11-7; PMID:1381253; DOI:10.1016/0248-4900(92)90119- L.
57. Dumonteil E, Escobedo-Ortegon J, Reyes-Rodriguez N, Ramirez-Sierra MJ, Arjona-Torres A. Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice. Infect Immun 2004; 72:46-53; PMID:14688079; DOI:10.1128/IAI.72.1.46-53. 2004.
58. Duthie MS, Kahn M, Zakayan A, White M, Kahn SJ. Parasite-induced chronic inflammation is not exacerbated by immunotherapy before or during Trypanosoma cruzi Infection. Clin Vaccine Immunol 2007; 14:1005-12; PMID:17538117; DOI:10.1128/CVI.00087-07.
59. Zapata-Estrella H, Hummel-Newell C, Sanchez-Burgos G, Escobedo-Ortegon J, Ramirez-Sierra MJ, Arjona-Torres A, et al. Control of Trypanosoma cruzi infection and changes in T cell populations induced by a therapeutic DNA vaccine in mice. Immunol Lett 2006; 103:186-91; PMID:16378645; DOI:10.1016/j.imlet. 2005.11.015.
60. + T cells. Vaccine 2010; 28:7414-9; PMID:20850536; DOI:10.1016/j.vaccine.2010.08.104.
61. Barr SC, Gossett KA, Klei TR. Clinical, clinicopathologic and parasitologic observations of trypanosomiasis in dogs infected with North American Trypanosoma cruzi isolates. Am J Vet Res 1991; 52:954-60; PMID:1909105.
62. Guedes PM, Veloso VM, Tafuri WL, Galvao LM, Carneiro CM, Lana M, et al. The dog as model for chemotherapy of the Chagas' disease. Acta Trop 2002; 84:9-17; PMID:12387906; DOI:10.1016/S0001-706X(02)00139-0.
63. Cruz-Chan JV, Bolio-González ME, Colin-Flores R, Ramirez-Sierra MJ, Quijano-Hernandez IA, Dumonteil E. Immunopathology of natural Trypanosoma cruzi infection in dogs. Vet Parasitol 2009; 162:151-5; PMID:19324497; DOI:10.1016/j.vetpar.2009.02.024.
64. Basombrio MA, Segura MA, Mora MC, Gomez L. Field trial of vaccination against American trypanosomiasis (Chagas' disease) in dogs. Am J Trop Med Hyg 1993; 49:143-51; PMID:8352387.
65. Basso B, Castro I, Introini V, Gil P, Truyens C, Moretti E. Vaccination with Trypanosoma rangeli reduces the infectiousness of dogs experimentally infected with Trypanosoma cruzi. Vaccine 2007; 25:3855-8; PMID:17349724; DOI:10.1016/j.vaccine.2007.01.114.
66. Aparicio-Burgos JE, Ochoa-Garcia L, Zepeda-Escobar JA, Gupta S, Dhiman M, Martinez JS, et al. Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine against Trypanosoma cruzi Infection in Dogs. PLoS Negl Trop Dis 2011; 5:1050; PMID:21625470; DOI:10.1371/journal.pntd.0001050.
67. Quijano-Hernandez IA, Bolio-González ME, Rodríguez-Buenfil JC, Ramirez-Sierra MJ, Dumonteil E. Therapeutic DNA vaccine against Trypansomoma cruzi in dogs: a pilot clinical trial. Ann NY Acad Sci 2008; 1149:343-6; PMID:19120245; DOI:10.1196/annals.1428.098.
68. Camargo EP. Perspectives of vaccination in Chagas disease revisited. Mem Inst Oswaldo Cruz 2009; 104:275-80; PMID:19753485; DOI:10.1590/S0074- 02762009000900036.
69. Junqueira C, Caetano B, Bartholomeu DC, Melo MB, Ropert C, Rodrigues MM, et al. The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease. Expert Rev Mol Med 2010; 12:29; PMID:20840799; DOI:10.1017/S1462399410001560.
70. Engman DM, Leon JS. Pathogenesis of Chagas heart disease: role of autoimmunity. Acta Trop 2002; 81:123-32; PMID:11801219; DOI:10.1016/S0001- 706X(01)00202-9.
71. Thomas S, Redfern JB, Lidbury BA, Mahalingam S. Antibody-dependent enhancement and vaccine development. Expert Rev Vaccines 2006; 5:409-12; PMID:16989620; DOI:10.1586/14760584.5.4.409.
72. Huisman W, Martina BE, Rimmelzwaan GF, Gruters RA, Osterhaus AD. Vaccine-induced enhancement of viral infections. Vaccine 2009; 27:505-12; PMID:19022319; DOI:10.1016/j.vaccine.2008.10.087
73. Guy B, Chanthavanich P, Gimenez S, Sirivichayakul C, Sabchareon A, Begue S, et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 2004; 22:3563-74; PMID:15315835; DOI:10.1016/j.vaccine.2004.03.042.
74. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010; 328:745-8; PMID:20448183; DOI:10.1126/science.1185181.
75. Tarleton RL. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 2001; 31:550-4; PMID:11334941; DOI:10.1016/S0020-7519(01)00158-8.
76. Rocha MO, Ribeiro AL, Teixeira MM. Clinical management of chronic chagas cardiomyopathy. Front Biosci 2003; 8:44-54; PMID:12456332; DOI:10.2741/926.
77. Hyland KV, Leon JS, Daniels MD, Giafis N, Woods LM, Bahk TJ, et al. Modulation of autoimmunity by treatment of an infectious disease. Infect Immun 2007; 75:3641-50; PMID:17485457; DOI:10.1128/IAI.00423-07.
78. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV. Pathogenesis of chronic Chagas heart disease. Circulation 2007; 115:1109-23; PMID:17339569; DOI:10.1161/CIRCULATIONAHA.106.624296.
79. McKinnon LR, Card CM. HIV vaccine efficacy trials: A brief history, and options for going forward. AIDS Rev 2010; 12:209-17; PMID:21179185.
80. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 2010; 24:621-35; PMID:20179575; DOI:10.1097/QAD.0b013e328337798a.
81. Bowalekar S. Adaptive designs in clinical trials. Perspect Clin Res 2011; 2:23-7; PMID:21584178; DOI:10.4103/2229-3485.76286.
82. Ribeiro AL, Rocha MO, Terranova P, Cesarano M, Nunes MD, Lombardi F. T-wave amplitude variability and the risk of death in Chagas Disease. J Cardiovasc Electrophysiol 2011; In press; PMID:21235679; DOI:10.1111/j.1540- 8167.2010.02000.x.
83. Sarabanda AV, Marin-Neto JA. Predictors of mortality in patients with Chagas' cardiomyopathy and ventricular tachycardia not treated with implantable cardioverter-defibrillators. Pacing Clin Electrophysiol 2011; 34:54-62; PMID:20946310; DOI:10.1111/j.1540-8159.2010.02896.x.
84. Barr SC, Warner KL, Kornreic BG, Piscitelli J, Wolfe A, Benet L, et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother 2005; 49:5160-1; PMID:16304193; DOI:10.1128/AAC.49.12.5160-1.2005.
85. Fernandes CD, Tiecher FM, Balbinot MM, Liarte DB, Scholl D, Steindel M, et al. Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Mem Inst Oswaldo Cruz 2009; 104:27-32; PMID:19274372; DOI:10.1590/S0074- 02762009000100004.
86. Laucella SA, Mazliah DP, Bertocchi G, Alvarez MG, Cooley G, Viotti R, et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis 2009; 49:1675-84; PMID:19877967; DOI:10.1086/648072.
87. Garcia-Alvarez A, Sitges M, Pinazo MJ, Regueiro-Cueva A, Posada E, Poyatos S, et al. Chagas cardiomyopathy: the potential of diastolic dysfunction and brain natriuretic peptide in the early identification of cardiac damage. PLoS Negl Trop Dis 2010; 4:826; PMID:20877635; DOI:10.1371/journal.pntd.0000826.
88. Lima-Costa MF, Cesar CC, Peixoto SV, Ribeiro AL. Plasma B-type natriuretic peptide as a predictor of mortality in community-dwelling older adults with Chagas disease: 10-year follow-up of the Bambui Cohort Study of Aging. Am J Epidemiol 2010; 172:190-6; PMID:20581155; DOI:10.1093/aje/kwq106.
89. Lorena VM, Lorena IM, Braz SC, Melo AS, Melo MF, Melo MG, et al. Cytokine levels in serious cardiopathy of Chagas disease after in vitro stimulation with recombinant antigens from Trypanosoma cruzi. Scand J Immunol 2010; 72:529-39; PMID:21044127; DOI:10.1111/j.1365-3083.2010.02462.x.
90. Ndao M, Spithill TW, Caffrey R, Li H, Podust VN, Perichon R, et al. Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling. J Clin Microbiol 2010; 48:1139-49; PMID:20071547; DOI:10.1128/JCM.02207-09.
91. Wang Y, Moreira Mda C, Heringer-Walther S, Ebermann L, Schultheiss HP, Wessel N, et al. Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP. J Card Fail 2010; 16:157-63; PMID:20142028; DOI:10.1016/j.cardfail.2009.09.005.
92. Fabbro DL, Olivera V, Bizai ML, Denner S, Diez C, Mancipar I, et al. Humoral immune response against P2beta from Trypanosoma cruzi in persons with chronic Chagas disease: its relationship with treatment against parasites and myocardial damage. Am J Trop Med Hyg 2011; 84:575-80; PMID:21460013; DOI:10.4269/ajtmh.2011; 10-0261.
93. Bottazzi ME, Dumonteil E, Valenzuela JG, Betancourt-Cravioto M, Tapia-Conyer R, Hotez PJ. Bridging the innovation gap for neglected tropical diseases in Mexico: capacity building for the development of a new generation of antipoverty vaccines. Bol Med Hosp Infant Mex 2011; 68:130-8.
94. +-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. Infect Immun 2005; 73:6017-25; PMID:16113322; DOI:10.1128/IAI.73.9.6017-25.2005.
95. +T cells. Vaccine 2007; 25:6018-27; PMID:17629597; DOI:10.1016/j.vaccine.2007.05. 022.
96. + CTL and B cell-mediated cross-priming. J Immunol 2007; 179:6889-900; PMID:17982080.
97. Giddings OK, Eickhoff CS, Sullivan NL, Hoft DF. Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges. Infect Immun 2010; 78:1333-8; PMID:20048046; DOI:10.1128/IAI.00278-09.
98. Cazorla SI, Frank FM, Becker PD, Arnaiz M, Mirkin GA, Corral RS, et al. Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection. J Infect Dis 2010; 202:136-44; PMID:20497050; DOI:10.1086/652872.
99. Eickhoff CS, Giddings OK, Yoshida N, Hoft DF. Immune responses to gp82 provide protection against mucosal Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz 2010; 105:687-91; PMID:20835618; DOI:10.1590/S0074-02762010000500015.
100. Machado AV, Cardoso JE, Claser C, Rodrigues MM, Gazzinelli RT, Bruna-Romero O. Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 2006; 17:898-908; PMID:16972758; DOI:10.1089/hum.2006.17.898.
101. Duan X, Yonemitsu Y, Chou B, Yoshida K, Tanaka S, Hasegawa M, et al. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2. Vaccine 2009; 27:6154-9; PMID:19712768; DOI:10.1016/j.vaccine.2009. 08.026.
102. Garg N, Tarleton RL. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun 2002; 70:5547-55; PMID:12228281; DOI:10.1128/IAI.70.10. 5547-55.2002.
103. Chou B, Hiromatsu K, Hisaeda H, Duan X, Imai T, Murata S, et al. Genetic immunization based on the ubiquitin-fusion degradation pathway against Trypanosoma cruzi. Biochem Biophys Res Commun 2010; 392:277-82; PMID:20059980; DOI:10.1016/j.bbrc.2009.12.166.
104. Eickhoff CS, Vasconcelos JR, Sullivan NL, Blazevic A, Bruna-Romero O, Rodrigues MM, et al. Co-administration of a plasmid DNA encoding IL-15 improves long-term protection of a genetic vaccine against Trypanosoma cruzi. PLoS Negl Trop Dis 2011; 5:983; PMID:21408124; DOI:10.1371/journal.pntd.0000983.
105. Rigato PO, de Alencar BC, de Vasconcelos JR, Dominguez MR, Araujo AF, Machado AV, et al. Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi. Infect Immun 2011; 79:2120-30; PMID:21357719; DOI:10.1128/IAI.01190-10.
106. Sanchez-Burgos G, Mezquita-Vega G, Escobedo-Ortegon J, Ramirez-Sierra MJ, Arjona-Torres A, Rodrigues MM, et al. Comparative efficacy of DNA vaccines encoding various Trypanosoma cruzi antigens. FEMS Microbiol Med Immunol 2007; 50:333-41; DOI:10.1111/j.1574-695X.2007.00251.x.